Supplementary file 1_Nimotuzumab combined with gemcitabine and nab-paclitaxel as first-lin

A supplementary document from a single-arm, single-center Phase II prospective clinical trial evaluating a combination therapy for advanced pancreatic cancer. The study enrolled 16 patients and reports outcomes including an objective response rate of 68.75%, median progression-free survival of 6.0 months, and median overall survival of 12.0 months. The document was authored by Lin Lin and uploaded to figshare in 2026.

Use Cases

• Analyzing preliminary efficacy of a nimotuzumab-based regimen based on reported objective response rate and survival metrics.
• Assessing the safety profile of a triple-drug combination based on the reported adverse event grades and types.
• Informing the design of larger randomized controlled trials based on the study's conclusions and patient population details.

Strengths

• Includes specific clinical endpoints such as an objective response rate of 68.75% (11/16 patients) and a disease control rate of 100%.
• Reports detailed safety data with adverse events graded per NCI-CTCAE v5.0, noting no Grade 4 or higher toxicities.
• Provides a clear study protocol including drug dosages (e.g., nimotuzumab 400 mg), administration schedule, and patient eligibility criteria.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single-center study with 16 patients, which limits generalizability.

Provenance

Source

Single-center clinical trial registered at the Chinese Clinical Trial Register (ChiCTR2300072843).

Collection Method

Single-arm, prospective Phase II study.

Freshness

Last updated 2026-05-29 10:32:05; freshness should be verified.